BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 19773544)

  • 1. A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis.
    Tremmel M; Matzke A; Albrecht I; Laib AM; Olaku V; Ballmer-Hofer K; Christofori G; Héroult M; Augustin HG; Ponta H; Orian-Rousseau V
    Blood; 2009 Dec; 114(25):5236-44. PubMed ID: 19773544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling.
    Matzke-Ogi A; Jannasch K; Shatirishvili M; Fuchs B; Chiblak S; Morton J; Tawk B; Lindner T; Sansom O; Alves F; Warth A; Schwager C; Mier W; Kleeff J; Ponta H; Abdollahi A; Orian-Rousseau V
    Gastroenterology; 2016 Feb; 150(2):513-25.e10. PubMed ID: 26597578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
    Chen HM; Tsai CH; Hung WC
    Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice.
    Olaku V; Matzke A; Mitchell C; Hasenauer S; Sakkaravarthi A; Pace G; Ponta H; Orian-Rousseau V
    Mol Biol Cell; 2011 Aug; 22(15):2777-86. PubMed ID: 21680714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.
    Ghatak S; Hascall VC; Markwald RR; Misra S
    J Biol Chem; 2010 Jun; 285(26):19821-32. PubMed ID: 20200161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44 is required for two consecutive steps in HGF/c-Met signaling.
    Orian-Rousseau V; Chen L; Sleeman JP; Herrlich P; Ponta H
    Genes Dev; 2002 Dec; 16(23):3074-86. PubMed ID: 12464636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6.
    Volz Y; Koschut D; Matzke-Ogi A; Dietz MS; Karathanasis C; Richert L; Wagner MG; Mély Y; Heilemann M; Niemann HH; Orian-Rousseau V
    Biosci Rep; 2015 Jun; 35(4):. PubMed ID: 26181364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin.
    Singleton PA; Salgia R; Moreno-Vinasco L; Moitra J; Sammani S; Mirzapoiazova T; Garcia JG
    J Biol Chem; 2007 Oct; 282(42):30643-57. PubMed ID: 17702746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice.
    Khan F; Gurung S; Gunassekaran GR; Vadevoo SMP; Chi L; Permpoon U; Haque ME; Lee YK; Lee SW; Kim S; Lee B
    Theranostics; 2021; 11(3):1326-1344. PubMed ID: 33391537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2.
    Bougatef F; Quemener C; Kellouche S; Naïmi B; Podgorniak MP; Millot G; Gabison EE; Calvo F; Dosquet C; Lebbé C; Menashi S; Mourah S
    Blood; 2009 Dec; 114(27):5547-56. PubMed ID: 19837976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
    Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
    Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
    Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF.
    Endo A; Fukuhara S; Masuda M; Ohmori T; Mochizuki N
    J Recept Signal Transduct Res; 2003; 23(2-3):239-54. PubMed ID: 14626450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET Signaling Mediates Intestinal Crypt-Villus Development, Regeneration, and Adenoma Formation and Is Promoted by Stem Cell CD44 Isoforms.
    Joosten SPJ; Zeilstra J; van Andel H; Mijnals RC; Zaunbrecher J; Duivenvoorden AAM; van de Wetering M; Clevers H; Spaargaren M; Pals ST
    Gastroenterology; 2017 Oct; 153(4):1040-1053.e4. PubMed ID: 28716720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis.
    Mahabeleshwar GH; Feng W; Reddy K; Plow EF; Byzova TV
    Circ Res; 2007 Sep; 101(6):570-80. PubMed ID: 17641225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells.
    Sulpice E; Ding S; Muscatelli-Groux B; Bergé M; Han ZC; Plouet J; Tobelem G; Merkulova-Rainon T
    Biol Cell; 2009 Sep; 101(9):525-39. PubMed ID: 19281453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF and thrombin induce MKP-1 through distinct signaling pathways: role for MKP-1 in endothelial cell migration.
    Kinney CM; Chandrasekharan UM; Mavrakis L; DiCorleto PE
    Am J Physiol Cell Physiol; 2008 Jan; 294(1):C241-50. PubMed ID: 18003751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial SCUBE2 Interacts With VEGFR2 and Regulates VEGF-Induced Angiogenesis.
    Lin YC; Chao TY; Yeh CT; Roffler SR; Kannagi R; Yang RB
    Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):144-155. PubMed ID: 27834687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.